PMID- 1357158
OWN - NLM
STAT- MEDLINE
DCOM- 19921120
LR  - 20181109
IS  - 0022-3565 (Print)
IS  - 0022-3565 (Linking)
VI  - 263
IP  - 1
DP  - 1992 Oct
TI  - Tolerance and cross-tolerance to the activating effects of 
      3,4-methylenedioxymethamphetamine and a 5-hydroxytryptamine1B agonist.
PG  - 318-26
AB  - Previous studies indicate that 3,4-methylenedioxymethamphetamine (MDMA) produces 
      locomotor hyperactivity in rats by increasing the presynaptic release of 
      serotonin (5-HT). Interactions between MDMA and 5-HT receptor antagonists suggest 
      that the activating effects of MDMA are mediated via 5-HT1-like receptors. In 
      order to assess the contribution of particular 5-HT receptor subtypes to the 
      behavioral effects of MDMA, the present studies examined the development of 
      tolerance and cross-tolerance to the behavioral effects of MDMA and selective 
      5-HT receptor agonists. In the first study, rats were pretreated with saline, a 
      5-HT1A receptor agonist (8-hydroxy-2-(di-n-propylamino)tetralin, 1.0 mg/kg), a 
      5-HT1B receptor agonist [5-methoyx-3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole 
      butane dioate (RU24969), 2.5 mg/kg] or a 5-HT1C/5-HT2 receptor agonist 
      (2,5-dimethoxy-4-iodoamphetamine, 1.0 mg/kg) twice daily for 3 days. The 
      behavioral response to S-MDMA (3.0 mg/kg) was assessed 36 hr after the last 
      pretreatment injection. Pretreatment with RU24969 antagonized the activating 
      effects of S-MDMA. In contrast, pretreatment with 2,5-dimethoxy-4-iodoamphetamine 
      did not alter the response to S-MDMA, and pretreatment with 
      8-hydroxy-2-(di-n-propylamino)tetralin reduced the activity of both control and 
      S-MDMA-treated animals. In the second study, rats were pretreated with saline or 
      RS-MDMA (10 mg/kg), twice daily for 4 days. The behavioral response to saline, 
      S-MDMA (3.0 mg/kg), RU24969 (2.5 mg/kg) or S-amphetamine (1.0 mg/kg) was assessed 
      36 hr after the last pretreatment injection.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Callaway, C W
AU  - Callaway CW
AD  - Department of Psychiatry, School of Medicine, University of California San Diego, 
      La Jolla.
FAU - Geyer, M A
AU  - Geyer MA
LA  - eng
GR  - DA02925/DA/NIDA NIH HHS/United States
GR  - M07198/PHS HHS/United States
GR  - MH00188/MH/NIMH NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Pharmacol Exp Ther
JT  - The Journal of pharmacology and experimental therapeutics
JID - 0376362
RN  - 0 (Indoles)
RN  - 0 (Serotonin Receptor Agonists)
RN  - 2ISE72RACC (5-methoxy 3-(1,2,3,6-tetrahydro-4-pyridinyl)1H indole)
RN  - 4764-17-4 (3,4-Methylenedioxyamphetamine)
RN  - CK833KGX7E (Amphetamine)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - 3,4-Methylenedioxyamphetamine/*analogs & derivatives/pharmacology
MH  - Amphetamine/pharmacology
MH  - Animals
MH  - Behavior, Animal/drug effects
MH  - Brain/*drug effects/metabolism
MH  - Drug Interactions
MH  - Drug Tolerance
MH  - Indoles/*pharmacology
MH  - Male
MH  - N-Methyl-3,4-methylenedioxyamphetamine
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Serotonin Receptor Agonists/*pharmacology
EDAT- 1992/10/01 00:00
MHDA- 1992/10/01 00:01
CRDT- 1992/10/01 00:00
PHST- 1992/10/01 00:00 [pubmed]
PHST- 1992/10/01 00:01 [medline]
PHST- 1992/10/01 00:00 [entrez]
PST - ppublish
SO  - J Pharmacol Exp Ther. 1992 Oct;263(1):318-26.